Showing results (41-50 of 661) with videos related to
Sort By:
Pageof 67
Oncotarget|February 5, 2019
FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cellsMing Zhao, Ming-Lei Zhuo, Xiaofeng Zheng, et al.Expert Opinion on Investigational Drugs|August 14, 2018
Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapySiqing Fu, Yudong Wang, Khandan Keyomarsi, et al.Cell Genomics|February 13, 2023
Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencingJake Leighton, Min Hu, Emi Sei, et al.Human Pathology|August 4, 2025
Emerging molecular Therapeutic targets in breast Cancer: Pathologic identification and clinical implicationsAysegul A Sahin, Hui Chen, Huang Xiao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2013
Accelerated approval and breakthrough therapy designation: oncology drug development on speed?James C Yao, Funda Meric-Bernstam, J Jack Lee, et al.Molecular Cancer|March 27, 2024
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE studyBlessie Elizabeth Nelson, Jason Roszik, Jibran Ahmed, et al.Journal of the National Cancer Institute|November 9, 2017
Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma TumorsShiraj Sen, Funda Meric-Bernstam, David S Hong, et al.Journal of Immunotherapy and Precision Oncology|September 2, 2024
Decentralized Clinical Trials in Early Drug Development-A Framework ProposalDiogo J Silva, Blessie Elizabeth Nelson, Jordi RodonNPJ Precision Oncology|January 11, 2023
Antibody-drug conjugates in lung cancer: dawn of a new era?Niamh Coleman, Timothy A Yap, John V Heymach, et al.Clinical Breast Cancer|December 1, 2010
Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesisPriscilla F McAuliffe, Funda Meric-Bernstam, Gordon B Mills, et al.Pageof 67